BACKGROUND: Data evaluating the biological events and determinants of early human immunodeficiency virus type 1 (HIV-1) infection are limited in sub-Saharan Africa. We examined plasma viral levels and trends during early and established HIV-1 infection among reproductive-age women who participated in a randomized trial to treat genital tract infection in Malawi. We also assessed the association of injectable hormonal contraceptive use with HIV-1 infection. METHODS: We studied 3 groups of women who were infected or uninfected with HIV-1: seroconverters, seroprevalent women, and seronegative women. Questionnaires and blood samples were collected at baseline and every 3 months for 1 year. The virus set point in seroconverters and levels and trends of viral load over time were determined. The associations of injectable hormonal contraceptive use with HIV-1 infection and viral load were assessed using conditional logistic regression and mixed-effect models, respectively. RESULTS: In the original clinical trial, 844 women infected with HIV-1 and 842 women not infected with HIV-1 were enrolled. Of 31 women who experienced seroconversion during 12 months, 27 were matched with 54 seroprevalent and 54 seronegative women. The estimated median plasma virus set point was 4.45 log(10) copies/mL (interquartile range, 4.32-5.14 log(10) copies/mL). Injectable hormonal contraceptive use was significantly associated with HIV-1 seroconversion (adjusted odds ratio, 10.42; P = .03) but not with established HIV-1 infection. Among the seroconverters, a statistically significant interaction was found between the linear association of viral load and time of injectable hormonal contraceptive use (regression coefficient, -0.14; P = .02). CONCLUSION: Knowledge of virus set point and trends of viral load in HIV-1 seroincident and seroprevalent asymptomatic women could assist in antiretroviral treatment management.
RCT Entities:
BACKGROUND: Data evaluating the biological events and determinants of early human immunodeficiency virus type 1 (HIV-1) infection are limited in sub-Saharan Africa. We examined plasma viral levels and trends during early and established HIV-1 infection among reproductive-age women who participated in a randomized trial to treat genital tract infection in Malawi. We also assessed the association of injectable hormonal contraceptive use with HIV-1 infection. METHODS: We studied 3 groups of women who were infected or uninfected with HIV-1: seroconverters, seroprevalent women, and seronegative women. Questionnaires and blood samples were collected at baseline and every 3 months for 1 year. The virus set point in seroconverters and levels and trends of viral load over time were determined. The associations of injectable hormonal contraceptive use with HIV-1 infection and viral load were assessed using conditional logistic regression and mixed-effect models, respectively. RESULTS: In the original clinical trial, 844 women infected with HIV-1 and 842 women not infected with HIV-1 were enrolled. Of 31 women who experienced seroconversion during 12 months, 27 were matched with 54 seroprevalent and 54 seronegative women. The estimated median plasma virus set point was 4.45 log(10) copies/mL (interquartile range, 4.32-5.14 log(10) copies/mL). Injectable hormonal contraceptive use was significantly associated with HIV-1 seroconversion (adjusted odds ratio, 10.42; P = .03) but not with established HIV-1 infection. Among the seroconverters, a statistically significant interaction was found between the linear association of viral load and time of injectable hormonal contraceptive use (regression coefficient, -0.14; P = .02). CONCLUSION: Knowledge of virus set point and trends of viral load in HIV-1 seroincident and seroprevalent asymptomatic women could assist in antiretroviral treatment management.
Authors: Charles S Morrison; Pai-Lien Chen; Cynthia Kwok; Barbra A Richardson; Tsungai Chipato; Roy Mugerwa; Josaphat Byamugisha; Nancy Padian; David D Celentano; Robert A Salata Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Dana B Hancock; Nathan C Gaddis; Joshua L Levy; Laura J Bierut; Alex H Kral; Eric O Johnson Journal: AIDS Date: 2015-04-24 Impact factor: 4.177
Authors: Adriana Weinberg; Amanda A Allshouse; Samantha Mawhinney; Jennifer Canniff; Lorie Benning; Eryka L Wentz; Howard Minkoff; Mary Young; Marek Nowicki; Ruth Greenblatt; Mardge H Cohen; Elizabeth T Golub Journal: J Acquir Immune Defic Syndr Date: 2012-05-01 Impact factor: 3.731
Authors: Chelsea B Polis; Ronald H Gray; J B Bwanika; Godfrey Kigozi; Noah Kiwanuka; Fred Nalugoda; Joseph Kagaayi; Tom Lutalo; David Serwadda; Maria J Wawer Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: Elmar Saathoff; Michael Pritsch; Christof Geldmacher; Oliver Hoffmann; Rebecca N Koehler; Leonard Maboko; Lucas Maganga; Steffen Geis; Francine E McCutchan; Gustavo H Kijak; Jerome H Kim; Miguel A Arroyo; Martina Gerhardt; Sodsai Tovanabutra; Merlin L Robb; Carolyn Williamson; Nelson L Michael; Michael Hoelscher Journal: J Acquir Immune Defic Syndr Date: 2010-07 Impact factor: 3.731
Authors: Vladimir Novitsky; Rui Wang; Hermann Bussmann; Shahin Lockman; Marianna Baum; Roger Shapiro; Ibou Thior; Carolyn Wester; C William Wester; Anthony Ogwu; Aida Asmelash; Rosemary Musonda; Adriana Campa; Sikhulile Moyo; Erik van Widenfelt; Madisa Mine; Claire Moffat; Mompati Mmalane; Joseph Makhema; Richard Marlink; Peter Gilbert; George R Seage; Victor DeGruttola; M Essex Journal: PLoS One Date: 2010-04-12 Impact factor: 3.240
Authors: Adriana Weinberg; Jeong-Gun Park; Ronald Bosch; Alice Cho; Elizabeth Livingston; Fran Aweeka; Yoninah Cramer; D Heather Watts; Amneris E Luque; Susan E Cohn Journal: J Acquir Immune Defic Syndr Date: 2016-02-01 Impact factor: 3.731